mardi 12 décembre 2017

Onco Actu du 12 décembre 2017

2. Etiologie

Oral Microbiota Indicates Link Between Periodontal Disease and Esophageal Cancer [AACR]

2.8 Etiologie - Contraceptifs, THS

News Analysis: Birth Control Pills Protect Against Cancer, Too [NY Times]

3.1 Prévention - Tabac

FDA launches public education campaign to encourage adult smokers trying to quit cigarettes [FDA]

Austria to drop impending smoking ban, bucking Western trend [Reuters]

3.2 Prévention - Obésité

Cancer and Obesity: Not Such a Linear Relationship [The ASCO Post]

4.5 Dép., diag. & prono. - Colorectal

MMR Deficiency Screening is Under-utilised in Young Adult Patients with Colorectal Cancer [ESMO]

5. Traitements

Last Month in Oncology with Dr Bishal Gyawali: November 2017 [ecancernews]

5.12.1 Immunothérapies - partenariats

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017 [Boehringer Ingelheim]

5.12.7 Immunothérapies - vaccins

Gilead backs $60M Hookipa round to fund immunotherapy R&D [FierceBiotech]

5.2 Pharma

Lilly Nixes Expansion of Stomach Cancer Drug After Mixed Study Results [Xconomy]

Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans [Pharmafile]

Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma? [EndPoints]

GSK's new pharma head on lookout for cancer deals to boost pipeline [Reuters]

5.3 Traitements - FDA, EMA, NICE...

French Regulators Set Up Dedicated Unit for Overseeing Early Stage Clinical Trials [RAPS

5.8 ASH

Five Winners -- And One Loser -- From Medicine's Big Meeting About Blood [Forbes]

Acupuncture in cancer study reignites debate about controversial technique [Nature]

Roswell Park Hematology Experts Sharing New Research in ASH 2017 Podium Presentations [Roswell Park]

ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More [Xconomy]

5.8.1 ASH - Communiqués

Transfusion Dependence a Barrier to Quality End-of-Life Care for Some Patients with Leukemia [ASH]

People Aged 75 Years and Older Are Underrepresented in Blood Cancer Clinical Trials [ASH]

5.8.2 ASH - Pharma

ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting [ImmunoGen]

5.8.4 ASH - CAR T

ASH: Long-term CAR-T data look good for Gilead—but good enough to top its rivals? [FiercePharma]

Bluebird and Celgene’s CAR-T hits the mark in myeloma [FierceBiotech]

Juno Therapeutics and Celgene Corporation release additional data from transcend trial of jcar017 in patients with relapsed or refractory aggressive b-cell non-hodgkin lymphoma [Juno]

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia [Gilead]

5.8.5 ASH - Myélome multiple

KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial [Amgen]

GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting [GSK]

New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma [Janssen]

GSK offers encouraging data on BCMA-targeting armed antibody, setting stage for a return to late-stage cancer studies [EndPoints]

Amgen's Kyprolis improves overall survival in blood cancer patients [Reuters]

5.8.6 ASH - Leucémies

Immunotherapy could be beneficial for relapsed acute myeloid leukemia [UNC]

Sprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [BMS]

Promising responses seen with Agios leukemia drug in study [Reuters]

5.8.7 ASH - Lymphomes

ASH: Seattle Genetics CEO sees a big new Adcetris market, but one analyst has some doubts [FiercePharma]

Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting [Seattle Genetics]

Phase 2 data for Roche’s lymphoma ADC doesn’t disappoint [FierceBiotech]

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma [BMS]

6. Lutte contre les cancers

National Lung Cancer Roundtable Brings Together Patients, Organizations, and Clinicians for First Annual Meeting [ACS]

6.7.2 Applis

Your smartphone as medicine: Digital therapy is here to stay [STAT]